Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (28)
Ming Yi, Tianye Li, Mengke Niu, Qi Mei, Bin Zhao, Qian Chu, Zhijun Dai & Kongming Wu. (2023) Exploiting innate immunity for cancer immunotherapy. Molecular Cancer 22:1.
Crossref
Crossref
Munendra Singh Tomar, Rishi Kant Singh, Ilya V. Ulasov, Kaushalendra & Arbind Acharya. (2022) Refurbishment of NK cell effector functions through their receptors by depleting the activity of nTreg cells in Dalton’s Lymphoma-induced tumor microenvironment: an in vitro and in vivo study. Cancer Immunology, Immunotherapy 72:6, pages 1429-1444.
Crossref
Crossref
Christian Sordo-Bahamonde, Seila Lorenzo-Herrero, Ana P. Gonzalez-Rodriguez, Alejandra Martínez-Pérez, Juan P. Rodrigo, Juana M. García-Pedrero & Segundo Gonzalez. (2023) Chemo-Immunotherapy: A New Trend in Cancer Treatment. Cancers 15:11, pages 2912.
Crossref
Crossref
Reza Alimohammadi, Ghanbar Mahmoodi Chalbatani, Masoumeh Alimohammadi, Haniyeh Ghaffari-Nazari, Arezou Rahimi, Esmail Mortaz, Nariman Mossafa, Louis Boon & Seyed Amir Jalali. (2023) Dual blockage of both PD-L1 and CD47 enhances the therapeutic effect of oxaliplatin and FOLFOX in CT-26 mice tumor model. Scientific Reports 13:1.
Crossref
Crossref
Mohamed L. Salem, Kadry A. El-Bakry, Eman H. Moubark, Ashraf Sobh & Sohaila M. Khalil. (2022) Beneficial Modulatory Effects of Treatment With Bone Marrow Lysate on Hematopoietic Stem Cells and Myeloid Cells in Tumor-Bearing Mice. British Journal of Biomedical Science 79.
Crossref
Crossref
Hua Bai, Yuhui Peng, Yi Li, Juanjuan Duan, Wenli Fu, Xinming Liang, Wenfeng Yu & Qifang Zhang. (2022) Cytarabine‐induced TNFα promotes the expansion and suppressive functions of myeloid‐derived suppressor cells in acute myeloid leukaemia. Scandinavian Journal of Immunology 95:6.
Crossref
Crossref
Kai Li, Houhui Shi, Benxia Zhang, Xuejin Ou, Qizhi Ma, Yue Chen, Pei Shu, Dan Li & Yongsheng Wang. (2021) Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Sabina Sangaletti, Roberto Ferrara, Claudio Tripodo, Marina Chiara Garassino & Mario Paolo Colombo. (2021) Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. Cancer Immunology, Immunotherapy 70:9, pages 2429-2438.
Crossref
Crossref
Rinku Dutta, Roukiah Khalil, Karthick Mayilsamy, Ryan Green, Mark Howell, Srinivas Bharadwaj, Shyam S. Mohapatra & Subhra Mohapatra. (2021) Combination Therapy of Mithramycin A and Immune Checkpoint Inhibitor for the Treatment of Colorectal Cancer in an Orthotopic Murine Model. Frontiers in Immunology 12.
Crossref
Crossref
Laura Strauss, Valentina Guarneri, Alessandra Gennari & Antonio Sica. (2020) Implications of metabolism-driven myeloid dysfunctions in cancer therapy. Cellular & Molecular Immunology 18:4, pages 829-841.
Crossref
Crossref
Agata Pastorczak, Krzysztof Domka, Klaudyna Fidyt, Martyna Poprzeczko & Malgorzata Firczuk. (2021) Mechanisms of Immune Evasion in Acute Lymphoblastic Leukemia. Cancers 13:7, pages 1536.
Crossref
Crossref
Simone A. Minnie & Geoffrey R. Hill. (2021) Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?. Frontiers in Immunology 12.
Crossref
Crossref
Sujin Kang, Sooyeun Lee & Soyeun Park. (2020) iRGD Peptide as a Tumor-Penetrating Enhancer for Tumor-Targeted Drug Delivery. Polymers 12:9, pages 1906.
Crossref
Crossref
Yusuke Satoh, Hitoshi Kotani, Yuichi Iida, Takahito Taniura, Yoshitomo Notsu & Mamoru Harada. (2020)
Supplementation of
l
‐arginine boosts the therapeutic efficacy of anticancer chemoimmunotherapy
. Cancer Science 111:7, pages 2248-2258.
Crossref
Crossref
Min Zhang, Yibo Fan, Xiaofang Che, Kezuo Hou, Chaoxu Zhang, Ce Li, Ti Wen, Shuo Wang, Yu Cheng, Yunpeng Liu & Xiujuan Qu. (2020) 5-FU-Induced Upregulation of Exosomal PD-L1 Causes Immunosuppression in Advanced Gastric Cancer Patients. Frontiers in Oncology 10.
Crossref
Crossref
Dawn Swan, Mark Gurney, Janusz Krawczyk, Aideen E. RyanMichael O’Dwyer. (2020) Beyond DNA Damage: Exploring the Immunomodulatory Effects of Cyclophosphamide in Multiple Myeloma. HemaSphere 4:2, pages e350.
Crossref
Crossref
Christian Bailly, Xavier Thuru & Bruno Quesnel. (2020) Combined cytotoxic chemotherapy and immunotherapy of cancer: modern times. NAR Cancer 2:1.
Crossref
Crossref
Weng In Leong, Rachel Y. Ames, Jessica M. Haverkamp, Laura Torres, Janine Kline, Ashil Bans, Lauren Rocha, Marilena Gallotta, Cristiana Guiducci, Robert L. Coffman & Mary J. Janatpour. (2019) Low-dose metronomic cyclophosphamide complements the actions of an intratumoral C-class CpG TLR9 agonist to potentiate innate immunity and drive potent T cell-mediated anti-tumor responses. Oncotarget 10:68, pages 7220-7237.
Crossref
Crossref
Kristin G. Anderson, Valentin Voillet, Breanna M. Bates, Edison Y. Chiu, Madison G. Burnett, Nicolas M. Garcia, Shannon K. Oda, Christopher B. Morse, Ingunn M. Stromnes, Charles W. Drescher, Raphael Gottardo & Philip D. Greenberg. (2019) Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer. Cancer Immunology Research 7:9, pages 1412-1425.
Crossref
Crossref
Touko Inao, Hitoshi Kotani, Yuichi Iida, Irna Diyana Kartika, Tamio Okimoto, Ryosuke Tanino, Eiichi Shiba & Mamoru Harada. (2019) Different sensitivities of senescent breast cancer cells to immune cell‐mediated cytotoxicity. Cancer Science 110:9, pages 2690-2699.
Crossref
Crossref
Laura Agresta, Kasper H. N. Hoebe & Edith M. Janssen. (2018) The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment. Frontiers in Immunology 9.
Crossref
Crossref
Weimin Lin, Miao Chen, Le Hong, Hang Zhao & Qianming Chen. (2018) Crosstalk Between PD-1/PD-L1 Blockade and Its Combinatorial Therapies in Tumor Immune Microenvironment: A Focus on HNSCC. Frontiers in Oncology 8.
Crossref
Crossref
Stefania Orecchioni, Giovanna Talarico, Valentina Labanca, Angelica Calleri, Patrizia Mancuso & Francesco Bertolini. (2018) Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma. British Journal of Cancer 118:10, pages 1329-1336.
Crossref
Crossref
Rydell Alvarez, Liliana Oliver, Anet Valdes & Circe Mesa. (2018) Cancer-induced systemic myeloid dysfunction: Implications for treatment and a novel nanoparticle approach for its correction. Seminars in Oncology 45:1-2, pages 84-94.
Crossref
Crossref
Yuichi Iida, Nanae Harashima, Takanobu Motoshima, Yoshihiro Komohara, Masatoshi Eto & Mamoru Harada. (2017)
Contrasting effects of cyclophosphamide on anti‐
CTL
‐associated protein 4 blockade therapy in two mouse tumor models
. Cancer Science 108:10, pages 1974-1984.
Crossref
Crossref
John Anderson. (2017) Unleashing the immune response against childhood solid cancers. Pediatric Blood & Cancer 64:10, pages e26548.
Crossref
Crossref
Caifeng Deng, Mengdi Jia, Guangfei Wei, Tiantian Tan, Yao Fu, Huile Gao, Xun Sun, Quan Zhang, Tao Gong & Zhirong Zhang. (2016) Inducing Optimal Antitumor Immune Response through Coadministering iRGD with Pirarubicin Loaded Nanostructured Lipid Carriers for Breast Cancer Therapy. Molecular Pharmaceutics 14:1, pages 296-309.
Crossref
Crossref
Zhigang Zhang, Xiuyan Yu, Zhen Wang, Pin Wu & Jian Huang. (2015) Anthracyclines potentiate anti-tumor immunity: A new opportunity for chemoimmunotherapy. Cancer Letters 369:2, pages 331-335.
Crossref
Crossref